Upgrade to SI Premium - Free Trial

Sarepta Therapeutics' (SRPT) In Line Quarter Shifts Focus To R&D Day

May 4, 2018 7:01 AM
Nomura/Instinet analyst, Christopher Marai, reiterated his Buy rating on shares of Sarepta Therapeutics (NASDAQ: SRPT) and raised his price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View

Next Articles